Literature DB >> 7599922

Mechanisms of bradykinin-induced contraction of the guinea-pig gallbladder in vitro.

D A Cabrini1, A M Silva, J B Calixto.   

Abstract

1. The mechanisms underlying bradykinin (BK)-mediated contractions in strips of guinea-pig gallbladder (GPG) were examined by use of selective bradykinin (BK) receptor agonists and antagonists. 2. Addition of BK and related kinins (0.1 pM-10 microM) after 2 h of equilibration of the preparation caused graded contractions characterized by two distinct phases: high affinity (0.1 pM-1 nM) and low affinity (3 nM-10 microM). The rank order of potency for the first phase (mean EC50, pM) was: BK (1.36) = Hyp3-BK (1.44) = Lys-BK (1.54) > Tyr8-BK (2.72) > Met-Lys-BK (4.30). The rank order of potency for the second phase (mean EC50, nM, at concentration producing 50% of the contraction caused by 80 mM KCl) was: Hyp3-BK (8.95) > Met-Lys-BK (12.78) > Tyr8-BK (33.75) > Lys-BK caused by 80 mM KCl) was: Hyp3-BK (8.95) > Met-Lys-BK (12.78) > Tyr8-BK (33.75) > Lys-BK (60.92) > BK (77.35). The contractile responses (g of tension) to 3 microM of BK (the highest concentration tested) were: Hyp3-BK, 1.76 +/- 0.09; BK, 1.65 +/- 0.12; Lys-BK, 1.45 +/- 0.13; Tyr8-BK, 1.36 +/- 0.15 and Met-Lys-BK, 1.36 +/- 0.15. The selective B1 agonist, des-Arg9-BK, caused only a weak contraction with maximal response (0.21 +/- 0.05 g), which corresponded to approximately 10% of that induced by BK. 3. BK-induced contraction in GPG was inhibited by indomethacin (3 microM) or ibuprofen (30 microM), and was partially reduced by phenidone (30 microM), but was not affected by atropine (1 JM), nicardipine (1 gM),Ca2+-free medium plus EGTA, dazoxiben (30 nM), L-655,240 (10 nM, a selective receptor antagonist ofthromboxane A2), MK-571 (0.1 microM, a selective leukotriene D4 receptor antagonist), tetrodotoxin(0.3microM), CP 96,345 (0.3 microM, a NK1 receptor antagonist), mepyramine (1 microM), glibenclamide (1 microM), H-7(3 microM), staurosporine (100 nM), or phorbol 12-myristate 13-acetate (1 microM). However, BK-induced contractions in GPG maintained in Ca2+-free medium were markedly attenuated by ryanodine (10microM).4. Prostaglandin E2, prostaglandin F2alpha or U46619 (0.1 nM to 100microM), caused concentration-dependent contractions in GPG with mean EC50s of 3.1 microM; 1.7 microM and 0.47 nM and maximal responses of1.36 +/-0.15; 1.32 +/- 0.20 and 0.96 +/- 0.09 g, respectively.5. The selective B2 receptor antagonists, Hoe 140, NPC 17731 and NPC 17761 (0.01 -1 microM), caused concentration-dependent displacements to the right of the contractile concentration-response curve for BK. The selective B1 receptor antagonist, des-Arg9-[Leu8]-BK (1 microM), did not affect BK-induced GPG contraction.6. These data suggest that both high and low affinity BK responses in GPG are mediated by activation of B2 receptors, and that BK-mediated contraction in GPG depends on the release of intracellular Ca2+sources sensitive to ryanodine. In addition, BK-induced contraction in GPG is mediated by release of proinflammatory eicosanoid(s) derived from the cyclo-oxygenase pathway from arachidonic acid metabolism unrelated to thromboxane A2, and seems not to be coupled to activation of a protein kinase C-dependent mechanism.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7599922      PMCID: PMC1510381          DOI: 10.1111/j.1476-5381.1995.tb14938.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  27 in total

1.  Cumulative dose-response curves. II. Technique for the making of dose-response curves in isolated organs and the evaluation of drug parameters.

Authors:  J M VAN ROSSUM
Journal:  Arch Int Pharmacodyn Ther       Date:  1963

2.  Ryanodine activation and inhibition of the Ca2+ release channel of sarcoplasmic reticulum.

Authors:  G Meissner
Journal:  J Biol Chem       Date:  1986-05-15       Impact factor: 5.157

Review 3.  The pharmacology of ryanodine.

Authors:  D J Jenden; A S Fairhurst
Journal:  Pharmacol Rev       Date:  1969-03       Impact factor: 25.468

Review 4.  Pharmacology of kinins: their relevance to tissue injury and inflammation.

Authors:  F Marceau; A Lussier; D Regoli; J P Giroud
Journal:  Gen Pharmacol       Date:  1983

Review 5.  Kinin formation: mechanisms and role in inflammatory disorders.

Authors:  D Proud; A P Kaplan
Journal:  Annu Rev Immunol       Date:  1988       Impact factor: 28.527

6.  UK-37, 248, a novel, selective thromboxane synthetase inhibitor with platelet anti-aggregatory and anti-thrombotic activity.

Authors:  M J Randall; M J Parry; E Hawkeswood; P E Cross; R P Dickinson
Journal:  Thromb Res       Date:  1981 Jul 1-15       Impact factor: 3.944

Review 7.  Pharmacology of bradykinin and related kinins.

Authors:  D Regoli; J Barabé
Journal:  Pharmacol Rev       Date:  1980-03       Impact factor: 25.468

8.  The role of prostaglandins in feline experimental cholecystitis.

Authors:  D L Kaminski; Y G Deshpande; J Qualy; L A Thomas
Journal:  Surgery       Date:  1985-10       Impact factor: 3.982

9.  Indomethacin intravenously--a new way for effective relief of biliary pain: a double-blind study in man.

Authors:  E Thornell; R Jansson; J Svanvik
Journal:  Surgery       Date:  1981-09       Impact factor: 3.982

10.  Pharmacology of L-655,240 (3-[1-(4-chlorobenzyl)-5-fluoro-3-methyl-indol-2-yl]2,2-dimethylpro pan oic acid); a potent, selective thromboxane/prostaglandin endoperoxide antagonist.

Authors:  R A Hall; J Gillard; Y Guindon; G Letts; E Champion; D Ethier; J Evans; A W Ford-Hutchinson; R Fortin; T R Jones
Journal:  Eur J Pharmacol       Date:  1987-03-17       Impact factor: 4.432

View more
  1 in total

1.  Bradykinin modulates pacemaker currents through bradykinin B2 receptors in cultured interstitial cells of Cajal from the murine small intestine.

Authors:  Seok Choi; Do Young Park; Cheol Ho Yeum; In Youb Chang; Ho Jin You; Chan Guk Park; Man Yoo Kim; In Deok Kong; Insuk So; Ki Whan Kim; Jae Yeoul Jun
Journal:  Br J Pharmacol       Date:  2006-06-19       Impact factor: 8.739

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.